GlassScriptPhysician profile
Bela Laschiver
NPI 1497896286
$10,526.01
in general payments reported to CMS, 2019-2025
38 companies · $2,037 in 2025
The $2,037 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,391 · 2022: $2,054 · 2023: $1,980 · 2024: $2,065 · 2025: $2,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,061 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,060.95 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,580.28 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,443.31 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,415.90 | 2021-2025 | Ofev, Jardiance |
| Amgen INC. | $899.56 | 2021-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $618.70 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $580.15 | 2021-2025 | |
| Lilly USA, LLC | $459.71 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $456.97 | 2021-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $444.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $415.19 | 2021-2024 | |
| Pfizer INC. | $359.09 | 2021-2025 | |
| Madrigal Pharmaceuticals | $356.76 | 2024-2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $253.12 | 2023-2025 | |
| Amarin Pharma, INC. | $220.54 | 2021-2022 | |
| Gilead Sciences, INC. | $144.27 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $128.88 | 2023 | Auryon Laser System 100-120 Vac |
| Merck Sharp & Dohme LLC | $122.37 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Sk Life Science, INC. | $113.16 | 2023 | Xcopri |
| Dexcom, INC. | $72.97 | 2022-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $52.94 | 2021-2022 | |
| Esperion Therapeutics, INC. | $43.82 | 2023 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $35.10 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $33.94 | 2023 | Eliquis |
| Sanofi Pasteur INC. | $29.09 | 2023 | |
| Eisai INC. | $28.33 | 2021 | |
| Hologic Sales and Service, LLC | $22.43 | 2024 | Aptima |
| Viatris Specialty LLC | $21.77 | 2025 | Yupelri |
| Pulmonx Corporation | $20.93 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Exact Sciences Corporation | $20.80 | 2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $18.92 | 2024 | |
| Xeris Pharmaceuticals, INC. | $17.50 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.46 | 2023 | Quviviq |
| Mannkind Corporation | $15.31 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $14.39 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.29 | 2021 | |
| Cequr Corporation | $12.08 | 2023 | Cequr Simplicity |
| Biogen, INC. | $12.00 | 2021 | |
| Scilex Pharmaceuticals INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bela Laschiver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.